Physcion
Based on 10 publication(s) in Google Scholar
Physcion (Parietin), an anthraquinone derivative derived from the traditional Chinese medicine rhubarb, is an effective oral active 6-phosphogluconate dehydrogenase inhibitor with blood-brain barrier permeability, with IC50 and Kd values of 38.5 μM and 26.0 μM, respectively. Additionally, Physcion is an inhibitor of the <>bTLR4/NF-κB signaling pathway, exhibiting anti-inflammatory, antibacterial, and anticancer effects, and can induce Apoptosis and Autophagy in cancer cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.40%
- CAS 番号: 521-61-9
- 分子式: C16H12O5
- 分子量:284.26
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Physcion
More- Mol Cancer. 2025 Mar 26;24(1):97. [Abstract]
- Cancer Lett. 2024 Aug 21:217177. [Abstract]
- Chin Herb Med. 2026 Jun 19.
- J Ethnopharmacol. 2026 May 27:121893. [Abstract]
- Drug Des Devel Ther. 2021 Jan 25:15:277-287. [Abstract]
- Biomed Res Int. 2021 Sep 9;2021:9066938. [Abstract]
- World J Gastrointest Oncol. 2023 Aug 15;15(8):1400-1411. [Abstract]
- Drug Chem Toxicol. 2025 Oct 14:1-9. [Abstract]
- Curr Eye Res. 2023 Mar;48(3):238-250. [Abstract]
- Authorea. September 07, 2022.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
WB
-
IF
-
In Vivo Efficacy Study
Antibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
|
TLR4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μg/mL
Compound: 6
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| A549 | IC50 |
1.5 μM
Compound: 80
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay
|
[PMID: 33691166] |
| HCT-116 | IC50 |
19 μM
Compound: 2
|
Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay
Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 17949858] |
| HepG2 | IC50 |
77.3 μM
Compound: 2
|
Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 17949858] |
| HepG2 2.2.15 | IC50 |
300 μg/mL
Compound: 53
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production
|
[PMID: 24549242] |
| HepG2 2.2.15 | IC50 |
300 μg/mL
Compound: 53
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion
|
[PMID: 24549242] |
| HepG2 2.2.15 | IC50 |
300 μg/mL
Compound: 53
|
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion
|
[PMID: 24549242] |
| HT-29 | IC50 |
>100 μg/mL
Compound: 6
|
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| HUVEC | IC50 |
>100 μg/mL
Compound: 6
|
Antiproliferative activity against human HUVEC cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HUVEC cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| KB | ED50 |
1.55 μg/mL
Compound: 2
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
10.1021/np50085a021 |
| MCF7 | IC50 |
>100 μg/mL
Compound: 6
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| NCI-H157 | IC50 |
3 μM
Compound: 80
|
Antiproliferative activity against human NCI-H157 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H157 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay
|
[PMID: 33691166] |
| PLC-PRF-5 | ED50 |
1.44 μg/mL
Compound: 2
|
Cytotoxicity against human PLC/PRF/5 cells
Cytotoxicity against human PLC/PRF/5 cells
|
10.1021/np50085a021 |
Physcion (10 or 20 μM, 48 h) induces apoptosis and autophagy in human nasopharyngeal carcinoma (CNE2 cells)[2]. Physcion (10-40 μM, 24 h) attenuates OGD/R (oxygen-glucose deprivation/reperfusion)-induced neuronal damage and inflammatory response in SH-SY5Y cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:The nasopharyngeal carcinoma cell line CNE2
-
Concentration:10 or 20 μM
-
Incubation Time:48 h
-
Result:Induced apoptosis in CNE2 cells in a dose-dependent manner.
-
Cell Line:The nasopharyngeal carcinoma cell line CNE2
-
Concentration:10 or 20 μM
-
Incubation Time:48 h
-
Result:Significantly increased the level of LC3B-II, which means physcion induced autophagy in CNE2 cells.
-
Cell Line:Oxygen-glucose deprivation/reperfusion (OGD/R)-induced SH-SY5Y cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Significantly reversed the OGD/R-induced upregulation of TLR4, p-p65, and p-IκB expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ischemia-reperfusion (I/R)-induced focal cerebral ischemia model in SD rats[3]
-
Dosage:20 or 40 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 7 days
-
Result:Significantly reduced the brain water content and the NSS (Neurological Severity Score) in I/R rats, compared to I/R group. Obviously decreased areas of infarction compared to I/R group.
-
Animal Model:SPF chickens (21 days old) infected intra-laryngeally with Chlamydia psittaci 6 BCE[4]
-
Dosage:4 or 9 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 6 days
-
Result:Dose-dependently alleviated respiratory distress, air sac and lung lesions, and bacterial load in the spleen in infected chickens.
化学情報
-
CAS 番号 521-61-9
-
性状 Solid
-
分子量 284.26
-
分子式 C16H12O5
-
SMILES
O=C1C2=C(C=C(C)C=C2O)C(C3=CC(OC)=CC(O)=C13)=O
-
別名
Parietin; フィシオン; Rheochrysidin
-
Structure Classification
-
Initial Source
Microsporum sp;Teloschistes flavicans
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway. [Abstract]2025 Mar 26;24(1):97. PMID: 40140842
Physcion purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 26;24(1):97. [Abstract]
The cell viability of KYSE-30 and KYSE-410 cells was evaluated after treatment with various concentrations of Physcion (20, 40, 60, 80 μM) for 24 to 72 h.
Physcion purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 26;24(1):97. [Abstract]
Intracellular ROS levels in ESCC cells fluctuated after 48 h of Physcion (20, 40 μM) treatment.
Physcion purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 26;24(1):97. [Abstract]
Western blot analysis revealed a reduction in CDK2 protein expression in ESCC cells following Physcion (20, 40 μM) treatment.
Physcion purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 26;24(1):97. [Abstract]
The effect of Physcion (20, 40 μM) on DNA synthesis in ESCC cells was detected using an EdU staining assay.
Physcion purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 26;24(1):97. [Abstract]
Effects of physcion combined with metformin on the growth of ESCC in vivo. The changes in body weight and tumor volume in nude mice after administration of Physcion (20 mg/kg) and Metformin (200 mg/kg) as single drugs or in combination.
-
Cancer Lett
6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells. [Abstract]2024 Aug 21:217177. PMID: 39179096 -
-
J Ethnopharmacol
Physcion alleviates ulcerative colitis by upregulating SIRT3 to suppress PANoptosis via inhibition of the cGAS-STING pathway. [Abstract]2026 May 27:121893. PMID: 42202913 -
Drug Des Devel Ther
Physcion Protects Rats Against Cerebral Ischemia-Reperfusion Injury via Inhibition of TLR4/NF-kB Signaling Pathway. [Abstract]2021 Jan 25:15:277-287. PMID: 33536742 -
Biomed Res Int
Anti-influenza A Virus Effects and Mechanisms of Emodin and Its Analogs via Regulating PPAR α/ γ-AMPK-SIRT1 Pathway and Fatty Acid Metabolism. [Abstract]2021 Sep 9;2021:9066938. PMID: 34540999 -
World J Gastrointest Oncol
Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis. [Abstract]2023 Aug 15;15(8):1400-1411. PMID: 37663938 -
Drug Chem Toxicol
Physcion alleviates cisplatin-induced apo in HK-2 cells by activating the apo signaling for treating acute kidney injury: Integrating network pharmacology and informatics. [Abstract]2025 Oct 14:1-9. PMID: 41084754 -
Curr Eye Res
Hyperosmolar potassium inhibits corneal myofibroblast transformation and prevent corneal scar. [Abstract]2023 Mar;48(3):238-250. PMID: 36149345 -
溶剤 & 溶解度
THF : 2.5 mg/mL (8.79 mM; ultrasonic and warming and heat to 60°C)
DMF : 1 mg/mL (3.52 mM; Need ultrasonic)
Ethanol : < 1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Lin R, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17(11):1484-96. [Content Brief]
[2]. Pang MJ, et al. Physcion, a naturally occurring anthraquinone derivative, induces apoptosis and autophagy in human nasopharyngeal carcinoma. Acta Pharmacol Sin. 2016 Dec;37(12):1623-1640. [Content Brief]
[3]. Dong X, et al. Physcion Protects Rats Against Cerebral Ischemia-Reperfusion Injury via Inhibition of TLR4/NF-kB Signaling Pathway. Drug Des Devel Ther. 2021 Jan 25;15:277-287. [Content Brief]
[4]. Liu X, et al. Physcion, a novel anthraquinone derivative against Chlamydia psittaci infection. Vet Microbiol. 2023 Apr;279:109664. doi: 10.1016/j.vetmic.2023.109664. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / THF | 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | 87.9477 mL |
| THF | 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | 17.5895 mL |
Physcion 関連分類
HY-N0108 関連分類
Powered by Bioz